# Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus

> **NCT03618056** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 1 (actual)

## Conditions studied

- HIV Infections
- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** AIDSVAX® B/E

## Key facts

- **NCT ID:** NCT03618056
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-19
- **Primary completion:** 2020-07-17
- **Final completion:** 2020-07-17
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2022-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03618056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03618056, "Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT03618056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*